We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ALLO market cap is 423.56M. The company's latest EPS is USD -1.5608 and P/E is -1.33.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 43k | -44k | 22k | 0 | 0 |
| Operating Income | -62.98M | -71.93M | -69.5M | -71.43M | -71.77M |
| Net Income | -61.32M | -89.26M | -65M | -66.36M | -66.29M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 38.49M | 243k | 95k |
| Operating Income | -202.01M | -258.24M | -255.79M | -335.45M | -314.49M |
| Net Income | -184.59M | -250.22M | -257.01M | -332.63M | -327.27M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 712.33M | 642.84M | 586.35M | 646.88M | 589.12M |
| Total Liabilities | 129.22M | 130.6M | 124.98M | 131.85M | 125.37M |
| Total Equity | 583.1M | 512.23M | 461.37M | 515.04M | 463.75M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 717.8M | 1.23B | 1.04B | 817.08M | 642.84M |
| Total Liabilities | 88.78M | 148.21M | 122.23M | 151.21M | 130.6M |
| Total Equity | 629.02M | 1.08B | 916.41M | 665.87M | 512.23M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -184.03M | -237.73M | -55.9M | -119.49M | -163.6M |
| Investing | 95.83M | 163.29M | 22.13M | 96.75M | 20.75M |
| Financing | 95.54M | 95.7M | 1.65M | 110.25M | 110.93M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -137.35M | -115.09M | -184.81M | -220.52M | -237.73M |
| Investing | 164.08M | -505.12M | 163.66M | 106.16M | 163.29M |
| Financing | 58.96M | 633.59M | 11.96M | 2.95M | 95.7M |
| Market Cap | 423.56M |
| Price to Earnings Ratio | -1.33 |
| Price to Sales Ratio | 4.14k |
| Price to Cash Ratio | 5.22 |
| Price to Book Ratio | 0.85 |
| Dividend Yield | - |
| Shares Outstanding | 209.67M |
| Average Volume (1 week) | 2.7M |
| Average Volume (1 Month) | 2.48M |
| 52 Week Change | -26.54% |
| 52 Week High | 5.775 |
| 52 Week Low | 1.83 |
| Spread (Intraday) | 0.12 (5.74%) |
| Company Name | Allogene Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.allogene.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
